SCHEMBL17547437

SCHEMBL17547437

COc1ccc(Nc2nc(Nc3cc(OC)c(OC)c(OC)c3)ncc2C(F)(F)F)cn1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 2/20 0.67
AURKA O14965 3/20 0.64
KDR P35968 3/20 0.64
AURKB Q96GD4 2/20 0.64
ULK2 Q8IYT8 1/20 0.55
PTK2 Q05397 6/20 0.52
BRD4 O60885 1/20 0.52
EGFR P00533 5/20 0.50
JAK2 O60674 1/20 0.50
NTRK1 P04629 1/20 0.50
TYK2 P29597 1/20 0.50
JAK3 P52333 1/20 0.50
PTK2B Q14289 1/20 0.50
NTRK3 Q16288 1/20 0.50
NTRK2 Q16620 1/20 0.50
CDK1 P06493 1/20 0.49
CDK4 P11802 1/20 0.49
BTK Q06187 2/20 0.48
LRRK2 Q5S007 1/20 0.47
SYK P43405 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29575434 1.00 ULK1 (0.67) ULK1AURKAKDRAURKBULK2
SCHEMBL17547493 0.84 PTK2 (0.65) ULK1ULK2PTK2BRD4EGFR
SCHEMBL29575717 0.84 PTK2 (0.65) ULK1ULK2PTK2BRD4EGFR
SCHEMBL29576233 0.84 BRD4 (0.65) ULK1AURKAKDRPTK2BRD4
SCHEMBL17547483 0.84 BRD4 (0.65) ULK1AURKAKDRPTK2BRD4
SCHEMBL11916388 0.82 ULK1 (0.63) ULK1AURKAKDRAURKBULK2
SCHEMBL19654200 0.81 JAK2 (0.61) ULK1AURKAPTK2BRD4EGFR
SCHEMBL17547449 0.80 ULK1 (1.00) ULK1AURKAKDRAURKBULK2
SCHEMBL21258167 0.80 ULK1 (0.74) ULK1AURKAKDRAURKBULK2
SCHEMBL29575547 0.80 ULK1 (1.00) ULK1AURKAKDRAURKBULK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230130766-A1 MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS SALK INSTITUTE FOR BIOLOGICAL STUDIES 2023-04-27 US disclosed
US-20230130766-A1 MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS SALK INSTITUTE FOR BIOLOGICAL STUDIES 2023-04-27 US disclosed
WO-2021163633-A1 MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2021-08-19 WO disclosed
US-10774092-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-09-15 US disclosed
US-10689397-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-06-23 US disclosed
US-20190284207-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-09-19 US disclosed
US-20190248806-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-08-15 US disclosed
US-20190152989-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-05-23 US disclosed
US-10266549-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2019-04-23 US disclosed
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-11-30 US disclosed
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-11-30 US disclosed
WO-2016033100-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2016-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689397-B2 ULK1 inhibitors and methods using same ULK1, ULK2, ULK3 ULK1 1/4885AURKA 325/4885KDR 2326/4885
US-10266549-B2 ULK1 inhibitors and methods using same ULK1, ULK2, ULK3 ULK1 1/4885AURKA 325/4885KDR 2326/4885
US-20230130766-A1 MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS ULK1, ULK2, ULK3 ULK1 1/4885AURKA 56/4885KDR 1296/4885
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 ULK1 1/4885AURKA 366/4885KDR 2566/4885
US-20190248806-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 ULK1 1/4885AURKA 366/4885KDR 2566/4885
US-20190152989-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 ULK1 1/4885AURKA 366/4885KDR 2566/4885
US-10774092-B2 ULK1 inhibitors and methods using same ULK1, ULK2, ULK3 ULK1 1/4885AURKA 325/4885KDR 2326/4885
US-20190284207-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 ULK1 1/4885AURKA 366/4885KDR 2566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.